HC Wainwright

HC Wainwright’s Andrew S. Fein initiated coverage of Proteostasis Therapeutics Inc (NASDAQ: PTI) with a Buy rating and a price target of $15. The company develops disease-modifying therapeutics for diseases related to protein processing. At a time when combination-driven treatments are...

HC Wainwright initiated coverage of Ligand Pharmaceuticals Inc. (NASDAQ: LGND) with a Buy rating and 12 month price target of $146, saying Ligand is a profitable unique company that has royalty rights to over 140 potential medicines that its 85+ partners are funding the development. Analyst...

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) shares are down 33 percent year-to-date after having peaked at $9.32 on March 2. HC Wainwright analyst Ed Arce initiated coverage of the company with a Buy rating and a price target of $8.50. Three critical milestones within the next two months...

In a report published Wednesday, HC Wainwright analyst Andrew S Fein resumed coverage of TG Therapeutics Inc. (NASDAQ: TGTX) with a Buy rating and a price target of $22. TG Therapeutics' product pipeline offered "internal and external combination options whose efficacy and safety profiles bode well...

In a report published Tuesday, HC Wainwright analyst Andrew S. Fein initiated coverage of Biogen Inc (NASDAQ: BIIB) with a Buy rating and a price target of $380. Biogen's Alzheimer's disease product pipeline assets provided an opportunity for combination therapy, an approach that would be required...

In a report published Monday, H.C. Wainwright analyst Andrew S. Fein downgraded the rating on Epizyme Inc (NASDAQ: EPZM) to Neutral, while reducing the price target from $45 to $22, citing the absence of any material value drivers in the near- to mid-term. Analyst Andrew Fein mentioned that...

In a report published Monday, H.C. Wainwright analyst Heiko F. Ihle assumed coverage of Energy Fuels Inc Ordinary Shares (Canada) (NYSE: UUUU) with a Buy rating and a price target of $6.30, after the completion of the acquisition of Uranerz Energy Corp (NYSE: URZ). The acquisition, which closed on...

In a report published Tuesday, HC Wainwright analyst Ching-Yi Lin initiated coverage of CASI Pharmaceuticals Inc (NASDAQ: CASI) with a Buy rating and a price target of $2.50. Casi is a clinical stage company focused on developing and commercializing oncology therapeutics for both the US and Chinese...

In a report published Monday, HC Wainwright analyst Mark Breidenbach initiated coverage of OncoSec Medical Inc (NASDAQ: ONCS) with a Buy rating and a price target of $25. The target price reflects the recent 20-for-1 reverse stock split, which reduced the total outstanding shares of common stock...

In a report published Wednesday, HC Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on RedHill Biopharma Ltd - ADR (NASDAQ: RDHL), while raising the price target from $23 to $32. The company announced on Tuesday that it had received UK regulatory approval to initiate the Phase 3...

The American Society of Clinical Oncology (ASCO) conference is wrapping up in Chicago. The three day conference brings together thousands of oncology professionals and pharmaceutical companies to share research and new best practices. H.C. Wainwright analyst Reni Benjamin attended several...

In a report published Monday, HC Wainwright analysts initiated coverage of StemCells Inc (NASDAQ: STEM) with a Buy rating and a price target of $1. StemCells is carrying out clinical tests to apply its human CNS stem cells platform for developing treatments for CNS disorders. "The company...